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Background: Over-expression of insulin-like growth factor 2 mRNA binding protein 3 (IMP3) is correlated with poor
prognosis in pancreatic ductal adenocarcinoma (PDAC). Previous studies examining other cancer types have implicated
IMP3 in the regulation of several cellular functions that are characteristic of tumour cells. However, the role of this
oncofetal protein in PDAC progression remained unclear.
Methods: Using siRNA, we examined the effect of IMP3 inhibition on the motility, invasive ability, and matrix
adhesion of PDAC cells. In addition, we also evaluated the expression of cytoskeleton-associated genes following
IMP depletion.
Results: Knockdown of IMP3 significantly decreased the motility, invasion, and extracellular matrix adhesion of
select PDAC cells in vitro. In addition, IMP3-depleted cells exhibited lower levels of CD44 protein and KIF11 mRNA.
Moreover, we also observed a reduction in downstream RhoA signaling following IMP3 knockdown, indicating
that IMP3 modulates the levels of proteins involved in cytoskeletal organization.
Conclusions: These results suggest that IMP3 facilitates PDAC progression by enhancing the pro-metastatic behaviour of
tumour cells.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the
most lethal malignancies with a 5-year survival rate of 1-
4% and a median survival of 3–6 months [1]. The poor
prognosis of PDAC has been attributed to advanced dis-
ease at presentation, limited impact of conventional che-
motherapies on disease progression, and subsequent
metastatic spread and disease recurrence [2,3]. The
shortage of therapeutic options for PDAC underscores
the need for molecularly targeted agents that can im-
prove clinical outcomes.
Insulin-like growth factor-2 (IGF-2) mRNA binding
protein 3 (IMP3) is an oncofetal protein that may be* Correspondence: dyapp@bccrc.ca
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reproduction in any medium, provided the orinvolved in the malignancy of PDAC. Over-expression of
IMP3 in PDAC tissues relative to non-malignant pancre-
atic tissue is well-documented [4-6]. Interestingly, we
have found that IMP3 expression was highest in poorly
differentiated, grade 3 tumours [6]. Notably, the results
of our study indicate that IMP3 expression is an inde-
pendent predictor of overall survival and is correlated
with poor patient prognosis [6]. However, it is unclear
whether IMP3 plays an active role in facilitating PDAC
progression.
Binding of IMP3 to mRNA transcripts exerts post-
transcriptional control that influences key cellular func-
tions involved in cancer progression. Loss-of-function
experiments indicate that IMP3 is involved in the regu-
lation of proliferation, motility, and invasion of leukemic
[7], cervical carcinoma [8], glioblastoma [9], and oral
carcinoma cells [10]. Hence, we hypothesize that IMP3
may be playing a similar role in PDAC.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Pasiliao et al. BMC Cancer  (2015) 15:266 Page 2 of 9The objective of this study was to determine the influ-
ence of IMP3 on the phenotype of PDAC cells. Using
siRNA-mediated inhibition, the current study demon-
strated that knockdown of IMP3 significantly reduced
migration, invasion, and adhesion of pancreatic cancer
cells. Subsequently, the effect of IMP3 inhibition on the
expression of key proteins involved in adhesion and
cytoskeletal organization was examined. Our results
showed that IMP3 regulates the expression of CD44 and
KIF11, independent of AKT, ERK-1/2, and FAK signal-
ing. Thus, IMP3 inhibition may provide an avenue to-
wards delaying the progression of PDAC.
Methods
Cell culture
Human pancreatic ductal epithelial (HPDE)-mock and
KRASV12-transformed HPDE cells (a gift from Dr.
Ming-Sound Tsao, University of Toronto, Canada) were
maintained in serum-free keratinocyte medium (Invitro-
gen). HPAFII, MiaPaCa-2, PANC-1, and Hs766T, were
obtained from American Type Culture Collection and
cultured in the growth media recommended by ATCC.
L3.6pl cells (a gift from Dr. Isiah J. Fidler, MD Anderson
Cancer Center, Houston, TX) were cultured in MEM
supplemented with 10% fetal bovine serum, 2% vitamins,
200 mM L-glutamine, 100 mM sodium pyruvate, and 1%
non-essential amino acids. Cells were maintained at 37°
C with 5% CO2 and passaged regularly at 70-80% conflu-
ence to ensure growth in the exponential phase.
Short interfering RNA transfection. The human IMP3
ON-TARGETplus SMARTpool siRNA (Thermo Fisher
Scientific) contains a mixture of four siRNA which targets
distinct coding region sequences of IMP3 (NM_006547).
ON-TARGETplus non-targeting pool (Thermo Fisher Sci-
entific) was used as the scrambled control. One day prior
to transfection, the cells were seeded to ensure that density
was at 40-50% confluence at the time of transfection.
Scrambled or IMP3 siRNA were transfected into Hs766T
and PANC-1 (200 nM) and L3.6pl (50 nM) using Lipofecta-
mine RNAiMAX (Invitrogen) according to the manufac-
turer’s instructions. Forty-eight hours after transfection, the
cells were harvested for functional studies or molecular
analyses as described below. The individual siRNAs com-
prising the pooled siRNA solution were used in conjunc-
tion with Hs766T cells and reduced the motility of the cells.
A control scrambled siRNA sequence was used to asses
baseline motility. The results are shown in Additional file 1:
Figure S1.
Cell migration and invasion assays. BioCoat matrigel-
coated chambers and BioCoat control inserts (BD Bio-
sciences) were used to assess migration and motility,
respectively. A total of 2.5 × 104 cells were suspended in
serum-free DMEM and added onto the upper chamber.
DMEM with 10% FBS added to the lower chamberserved as chemoattractant. After 22 h of incubation at
37°C and 5% CO2, cells that have invaded and migrated
through the chambers were fixed in formalin and stained
with H&E for visualization. All cells on the invasion in-
serts and 12 selected fields on the migration inserts were
counted using bright field microscopy at 10X (Axio-
vert40C, Zeiss). Three replicate inserts were performed
for each experiment, and the experiments were repeated
3 times.
Scratch wound healing assay
The motility of L3.6pl cells were assessed using scratch
wound healing assays. Forty-eight hours after siRNA
transfection, plates were scratched linearly using a
200 μl pipette tip. Cells were washed with PBS and cul-
tured in supplemented MEM. Phase-contrast images
were captured at 3 different sections along the scratch at
baseline (T0) and 24 h (T24) after wounding using Axio-
vert40C (Zeiss) at 20X. The area of the scratch was
quantified using ImageJ, and wound coverage was calcu-
lated as the difference in areas between T0 and T24.
Adhesion assay
Forty-eight hours after siRNA transfection, the cells
were detached with 0.25% trypsin-EDTA (Invitrogen).
After washing with PBS, 1.0 × 106 cells were then seeded
onto the extracellular matrix (ECM) adhesion array
(Millipore). The assay was performed in accordance with
the manufacturer’s instructions.
ELISAs
Total cellular protein was collected 48 h after siRNA
transfection. The levels of GTP-bound RhoA, IGF-2, and
NGFβ in the protein lysates were quantified with RhoA
G-LISA (Cytoskeleton), non-extraction IGF-2 ELISA
(Diagnostic Systems), and NGF Emax ImmunoAssay Sys-
tems (Promega), respectively. The assays were performed
according to the manufacturer’s recommended protocol.
Western blot analysis
Cells were lysed in buffer containing protease inhibitors
[50 mmol/L HEPES (pH 8.0), 10% glycerol, 1% Triton
X-100, 150 mmol/L NaCl, 1 mmol/L EDTA, 1.5 mmol/L
MgCl2, 100 mmol/L NaF, and 10 mmol/L Na4P2O7H2O
supplemented with 5 μg/mL leupeptin, 5 μg/mL aproti-
nin, 100 μg/mL phenylmethylsulfonylfluoride and 37 μg/
mL Na3VO4]. Protein concentrations were quantified
using Micro BCA Protein Assay (Thermo Scientific).
Total cellular protein was heat-denatured, resolved on
12% SDS-PAGE, and transferred onto nitrocellulose
membrane. Membranes were blocked in 5% skim milk
for 1 h at room temperature followed by an overnight
incubation at 4°C with primary antibodies against IMP3
(1:1000; M3626 Dako), CD44 (1:800; ab119863 Abcam),
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ab4803 abcam), phospho-AKT S473 (1:1000; 3787S Cell
Signaling Technology), and phospho-Erk1/2 T202/Y204
(1:1000; 9101S Cell Signaling Technology). Membranes
were probed with horseradish peroxidase-conjugated goat
anti-mouse IgG, goat anti-rabbit IgG (1:5000; Promega), or
goat anti-rat IgG (abcam) for 1 h at room temperature
followed by detection with SuperSignal West Pico Chemi-
luminescent Substrate (Thermo Scientific) and imaging
with ChemiDoc MP (Bio-Rad). Membranes were then
stipped and re-probed for β-actin (1:5000; ab8227 Abcam),
total FAK (1:1000; ab40794 Abcam), total Akt (1:1000;
9272 Cell Signaling Technology), or total Erk1/2 (1:1000;
9102 Cell Signaling Technology). Band densities were
quantified using Image Lab (Bio-Rad).
Messenger ribonucleotide immunoprecipitation assay
IMP3 and associated mRNAs were isolated from cell
lysates through immunoprecipitation. Intracellular pro-
teins were collected by incubating cells in polysome lysis
buffer. The lysates were pre-cleared by adding non-
immune rabbit IgG (20 μg) for 1 h at 4°C followed by
incubation with 50 μl of Protein G-agarose beads
(Sigma-Aldrich) suspended in NT2 buffer supplemented
with 5% BSA. The protein concentrations of the pre-
cleared lysates were determined using BCA assay (Thermo
Scientific). To precipitate IMP3, 1.5 mg of protein was
incubated overnight with Protein G-agarose beads coated
with 40 μg of rabbit anti-human IMP3 (MBL Intl) or nor-
mal rabbit IgG (Sigma-Aldrich) resuspended in NT2 buf-
fer supplemented with RNase Out (Invitrogen), VRC,
leupeptin, aprotinin, PMSF, and sodium orthovanadate.
After incubation at room temperature for 3 h, the beads
were collected by centrifugation, washed with NT2 buffer,
and incubated with 20 units of DNase I (Qiagen) in 100 μl
of NT2 buffer for 20 minutes at 30°C. After washing with
NT2 buffer, the beads were pelleted by pulse centrifuga-
tion and resuspended in NT2 buffer supplemented with
30 μg of protease K (Sigma-Aldrich) and 0.1% SDS for
30 min at 55°C. RNA was extracted using Trizol (Invitro-
gen) following the manufacturer’s protocol.
Quantitative real-time reverse transcriptase-polymerase
chain reaction (qRT-PCR)
The transcription of kinesin KIF11, KIF14, KIF23, IGF-2,
NGFβ, and GAPDH were measured using qRT-PCR.
First-strand cDNA was synthesized from 1 μg of cellular
RNA extracted using RNeasy Plus Mini kit (Qiagen)
with on-column DNA digestion or 11 μl of RNA col-
lected from RIP assay using Oligo(dT)20 primers (Invi-
trogen) and SuperScript III (Invitrogen) following the
manufacturer’s recommended protocol. qRT-PCR was
performed using primers listed in the Table 1, and amp-
lification was monitored using SYBR Green. The cyclingparameters included an initial denaturation at 50°C for
30 min, followed by 95°C for 15 min, and 50 cycles of
annealing and extension at 94°C for 20 s and 60°C for
1 min. Under these conditions, the amplification effi-
ciencies of the targets were shown to be comparable to
that of the endogenous control, GAPDH. Fold difference
was analyzed using 2-ΔΔCT.
Statistical analyses
All results were presented as mean ± SEM. Statistical
analyses were carried out with repeated measures ana-
lysis of variance (ANOVA), followed by the Dunnett
post-hoc test, with P < 0.05 as the criterion for statistical
significance. Data were presented as means of at least 3
independent experiments.
Results
Expression of IMP3 in pancreatic cancer cell lines
The expression of IMP3 protein in pancreatic cancer cell
lines derived from primary tumours (PANC-1 and
MiaPaCa-2) and distant metastatic (HPAF-II, Hs766T,
L3.6pl) sites is shown in Figure 1A. IMP3 was highly
expressed in human pancreatic cancer cell lines and
interestingly, in KRASV12-transformed human pancreatic
ductal epithelial cells as well. In contrast, human pancre-
atic ductal epithelial cells (HPDE-mock) express mark-
edly lower levels of IMP3.
IMP3 knockdown decreases motility, invasion, and matrix
adhesion
To examine the influence of IMP3 on cellular behaviour,
the levels of IMP3 in pancreatic cancer cell lines were
depleted with RNA interference. Relative to scrambled
siRNA-transfected controls, treatment with human
IMP3 SMARTpool siRNA duplexes for 48 h achieved
significant reductions of IMP3 levels in Hs766T (46%),
PANC-1 (45%), and L3.6pl (58%) (Figure 1B) without af-
fecting proliferation.
Depletion of IMP3 led to a significant decrease in the
motility of Hs766T, a PDAC cell line derived from a lymph-
atic metastasis (Figure 2A). However, knocking down IMP3
did not affect the movement of PANC-1 through the trans-
well or the ability of L3.6pl cells to cover a scratch on the
culture plate (Additional file 2: Figure S2).
Using modified Boyden chamber assays, we examined
whether IMP3 is involved in regulating the ability of cells to
penetrate tissue barriers in vitro. As shown in Figure 2B,
IMP3 depletion resulted in a 4-fold decrease in the ability
of Hs766T to invade the basement membrane. In contrast,
the invasive ability of PANC-1 was not significantly affected
by IMP3 depletion (Additional file 2: Figure S2). The effect
of IMP3 inhibition on L3.6pl cell invasion could not be de-
termined with this assay as the cells did not penetrate the
matrix.
Table 1 Primer sequences
Forward sequence (5′→3′) Reverse sequence (5′→3′) Source
IGF-II AAGTCGATGCTGGTGCTTCT CGGAAACAGCACTCCTCAA [7]
NGFβ ATACAGGCGGAACCACACTC TGCTCCTGTGAGTCCTGTTG [37]
KIF11 CAGCTGAAAAGGAAACAGCC ATGAACAATCCACACCAGCA [38]
KIF14 TTGCTACGATTAGTCCCGCT GCTTTGCAATTTCTGCCTTC [38]
GAPDH TTTAACTCTGGTAAAGTGGATATTGTTG ATTTCCATTGATGACAAGCTTCC [7]
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adhesion of pancreatic cancer cells to proteins in the
extracellular matrix (ECM). In Hs766T, the inhibition of
IMP3 led to marked reductions in cellular adhesion to
ECM proteins including collagen IV, fibronectin, lam-
inin, tenascin, and fibronectin but not to collagen I and
collagen II (Figure 2C). We did not observe significant
changes in the adhesion of PANC-1 and L3.6pl to ECM
proteins (Additional file 3: Figure S3).
IMP3 is involved in the regulation of genes involved in
cell migration
Based on earlier reports of interactions between IMP3 and
mRNAs that contribute to the migration of other cancer
cell lines [8,9], we decided to assess the effect of knockingFigure 1 Expression of IMP3 in PDAC cell lines. (A) Western blots
showing basal expression of IMP3 protein in mock-transfected human
pancreatic ductal epithelial cells (HPDE-mock), KrasV12-transfected HPDEs
(HPDE-KRAS), and several pancreatic cancer cell lines. (B) Treatment with
IMP3 siRNA reduced the IMP3 levels in Hs766T, PANC-1, and L3.6pl.
Scrambled siRNA-transfected counterparts were included as controls.down IMP3 on the expression of receptors for ECM pro-
teins and microtubule-associated motor proteins. Knock-
down of IMP3 in Hs766T cells resulted in a significant
decrease in the levels of CD44 protein (Figure 3A) and ac-
tive, GTP-bound RhoA but not total RhoA (Figure 3B). In
contrast, we did not observe significant changes in the
expression of β1 integrin and levels of total and phosphor-
ylated FAK between IMP3-depleted cells and controls
(Additional file 4: Figure S4). To assess the expression of
motor proteins following IMP3 knockdown, we quantified
the mRNA levels of kinesins implicated in PDAC cell mo-
tility and invasion. Results of qRT-PCR revealed that
knocking down IMP3 knockdown significantly reduced
the expression of kinesin KIF11 but not kinesin KIF14
(Figure 3C).
Effect of IMP3 is independent of IGF-2 and NGFβ
IMP3 has previously been shown to facilitate the translation
of IGF-2 mRNA [7,9] and increase the levels of NGFβ in
pancreatic ductal cells [11]. Hence, we first examined
whether facilitation of growth factor signaling mediates the
influence of IMP3 on the phenotype of Hs766T cells. The
results of ribonucleoprotein immunoprecipitation assays
showed an enrichment of IGF-2 and NGFβ mRNAs in the
IMP3 pull-down fraction (Figure 4A), indicating that IMP3
interacts with these sequences.
To determine whether the deactivation of an IGF-2 or
NGFβ dependent pathway underlies the observed effects
of IMP3 depletion on the migratory behaviour of Hs766T,
we measured the expression and translation of these
growth factors and their associated signaling cascades fol-
lowing IMP3 knockdown. As shown in Figure 4B, there
was no significant difference in IGF-2 mRNA levels
between IMP3-depleted cells and scrambled siRNA-
treated controls. Interestingly, knockdown of IMP3 re-
sulted in a 3-fold increase in the levels of NGFβ mRNA.
However, results of our ELISAs indicate that IMP3 knock-
down did not alter the intracellular protein levels of IGF-2
and NGFβ. (Figure 4C). Moreover, we did not observe
changes in the levels of total and phosphorylated AKT and
ERK (Figure 4D).
Discussion
Over-expression of IMP3 has previously been reported
in PDAC. However, the contribution of this oncofetal
Figure 2 Effect of IMP3 knockdown on motility, invasion, and matrix adhesion of Hs766T. (A) The motility of Hs766T in Boyden chambers was
significantly decreased following siRNA-mediated inhibition of IMP3. Inset Representative images (10X) of motile Hs766T 24 h after seeding. (B)
The invasive potential of Hs766T was evaluated using Matrigel-coated Boyden chambers. IMP3 depletion resulted in a significant decrease in the
invasive potential of Hs766T. Inset Representative images (10X) of invasive Hs766T 24 h after seeding. (C) Adhesion to collagen I (Coll I), collagen II
(Coll II), collagen IV (coll IV), fibronectin (FN), tenascin (TN), laminin (LN), tenascin (TN), and vitronectin (VN) was quantified spectrophotometrically.
Absorbance at 550 nm is proportional to the number of adherent cells. *P < 0.05, **P < 0.01 relative to scrambled siRNA-transfected controls.
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defined. In this study, we demonstrated that knockdown of
IMP3 impedes motility, invasion, and matrix adhesion of
pancreatic cancer cells. Furthermore, siRNA-mediated in-
hibition of IMP3 reduced the levels of CD44 protein, KIF11
mRNA, and RhoA activation, suggesting that the effect of
IMP3 on facilitating metastatic potential is likely associated
with alterations in cytoskeletal dynamics. It is noteworthy
that in PDAC cells, knockdown of IMP3 did not alter the
activation of canonical signal transduction pathways associ-
ated with cell proliferation and movement including AKT,
ERK-1/2, and FAK. Thus, IMP3 inhibition presents an
alternative means of selectively impeding cell migration to
potentially retard the metastatic potential of PDAC.
IMP3 is an mRNA-binding protein shown to be over-
expressed in PDAC and various other malignancies includingcervical [8], endometrial [12,13], bladder [14], lung
[15], renal cell [16,17] and breast carcinomas [18,19] as
well as glioblastoma [9] and malignant melanoma [20].
The re-expression of IMP3 in KRASV12-transformed cells
as well as in cells harboring an activating K-ras mutation
indicates that IMP3 induction may be concomitant with
acquisition of K-ras mutations. Recently, epidermal growth
factor receptor (EGFR) signaling has been shown to regu-
late IMP3 expression. In both oral squamous cell carcin-
oma [21] and breast carcinoma cells [19], pharmacological
inhibition of EGFR resulted in decreased expression of
IMP3. Given that EGFR over-expression has previously
been identified in PDAC [22], it is plausible that enhanced
EGFR signaling may also be influencing IMP3 expression.
The mechanisms enabling IMP3 re-expression in PDAC
remains to be elucidated.
Figure 3 IMP3 regulates CD44 and KIF11. (A) Total CD44 protein
was measured in whole cell lysates 48 h after transfection. Treatment
with IMP3 siRNA resulted in a significant decrease in CD44 protein
relative to scrambled siRNA-treated controls. Inset Representative blots of
CD44 and corresponding β-actin. *P < 0.05 relative to scrambled
siRNA-transfected controls. (B) Levels of KIF11 and KIF14 mRNA
were measured 48 h after siRNA transfection and expressed in amount
of fold-change relative to scrambled siRNA-treated controls. *P < 0.05
relative to scrambled siRNA-transfected controls.
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in the behavior of Hs766T, this effect was not observed
in PANC-1 and L3.6pl. Recent analysis of gene expres-
sion patterns revealed that a sub-set of genes involved in
cellular adhesion and motility are differentially expressedin PDAC cell lines [23]. For instance, while mutations in
K-ras, P16, and P53 have been identified in Hs766T and
PANC-1, DPC4/Smad4 inactivation has only been re-
ported in Hs766T and not in PANC-1 [24] and L3.6pl
[25]. Interestingly, decreased DPC4/Smad4 signaling has
been shown to enhance PDAC cell motility and invasion
[26]. In addition, loss of DPC4/Smad4 has also been
associated with PDAC progression [27,28]. Given the re-
sults of our study, it is likely that the role of IMP3 in
facilitating metastatic potential is more pronounced in
DPC4/Smad4-negative tumour cells. Further investigation
into mechanisms underlying the observed differences in
phenotypic response to IMP3 depletion is warranted, as it
may uncover biomarkers that can predict response to
pharmacologic agents that target IMP3.
The observed decrease in motility, invasion, and matrix
adhesion of Hs766T following IMP3 knockdown suggests
that IMP3 facilitates the pro-metastatic behavior of a
sub-set of pancreatic cancer cells. This role of IMP3 in
pancreatic cell movement is consistent with reports ob-
tained in other cell lines. Previous studies have shown
that IMP3 is crucial for maintaining the invasive
phenotype of cervical carcinoma [8], oral squamous cell
carcinoma [21], hepatocellular carcinoma [29], and
glioblastoma cells [9]. Furthermore, over-expression of
IMP3 in vivo has been shown to induce acinar-ductal
metaplasia [11] and increase the formation of malig-
nant tumours in a lung model of metastasis [9]. Unfor-
tunately, at the present time a lack of suitable
pancreatic tumor models for studying metastasis pre-
clude extension of our studies in the in vivo setting.
More importantly, we have previously established a
correlation between IMP3 expression and patient prog-
nosis in PDAC [6]. Consistent with these findings, the
results of our current study support the notion that
IMP3 enhances the aggressiveness of PDAC by promot-
ing cancer cell dissemination.
Besides interacting with IGF-2 mRNA, IMP3 has been
shown to bind to and regulate the translation of multiple
mRNA sequences [30]. In HeLa cells, Vikesaa et al. have
previously shown that IMP3 binds to CD44 mRNA [8].
As an adhesion molecule, CD44 interacts with ECM
proteins including hyaluronan, collagen, fibronectin, and
laminin [31-34]. In Hs766T, we have found that IMP3
knockdown resulted in a marked decrease in CD44 pro-
tein. Coupled with observations of decreased matrix
adhesion in IMP3-depleted cells, our results suggest that
IMP3 is involved in regulating the levels of CD44 pro-
tein in PDAC cells. In breast cancer cells, CD44 has
been shown to stimulate the guanine exchange activity
of p115RhoGEF leading to activation of RhoA, a GTPase
involved in cytoskeletal organization and adhesion. In
PDAC cells, we demonstrated that knocking down IMP3
resulted in lower levels of active, GTP-bound RhoA.
Figure 4 Effect of IMP3 is independent of IGF-2 and NGFβ. Cell lysates were subjected to immunoprecipitation using anti-human IMP3 and rabbit
IgG. RNA extracted from the precipitates were analyzed using qRT-PCR. (A) Higher amplifications of IGF-2 mRNA and NGFβ mRNA were detected
in IMP3 pull-down fraction relative to IgG. (B) Treatment with IMP3 siRNA did not alter the mRNA levels of IGF-2 while it increased NGFβ mRNA
relative to scrambled siRNA-treated counterparts. qRT-PCR was used to measure mRNA levels following siRNA transfection. (C) Reduction in IMP3
did not alter levels of IGF-2 and NGFβ protein in Hs766T. Intracellular protein levels were measured using ELISAs. (D) Knocking down IMP3 did
not alter the levels of phosphorylated and total ERK as well as phosphorylated and total AKT.
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behavior following IMP3depletion is likely due to inhib-
ition of CD44-RhoA signaling.
In addition to CD44, our results also indicate that
IMP3 regulates KIF11 mRNA. Over-expressed in PDAC
cell lines [35,36] and in pancreatic tumours (unpublished
data), KIF11 is a mitotic kinesin that has been shown to
promote cancer cell proliferation and tumour formation
[35]. More recently, inhibition of KIF11 has been re-
ported to decrease the migration and invasion of PDAC
cells without affecting cell proliferation [36], suggesting
that KIF11 also plays a role in coordinating cell move-
ment. Taken together, our results showed that IMP3
expression promotes matrix adhesion, motility and inva-
sion of pancreatic cancer cells by enhancing CD44 and
KIF11 expression. Profiling and pathway analysis of
genes associated with cytoskeletal organization, motility,and ECM interaction following IMP3 knockdown in
PDAC cells would be instrumental in identifying add-
itional molecules that promote the metastatic spread of
PDAC.Conclusions
Our results demonstrate that IMP3 is involved in facili-
tating the pro-metastatic behavior of a subset of pancre-
atic cancer cells. This effect is likely due to increased
translation of mRNAs that contribute to motility, inva-
sion and matrix adhesion including CD44 and KIF11.
Given the poor efficacy of currently available treatments
in PDAC, pharmacologic inhibitors of IMP3 may repre-
sent a viable therapeutic strategy by altering pancreatic
cancer cell behavior and halting/delaying pancreatic
tumour metastasis.
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Additional file 1: Figure S1. Effect of IMP3 on motility of Hs766T. Cells
transfected with different siRNA sequences targeting IMP3 or scrambled
siRNA were washed and resuspended in serum-free DMEM. Cells were
then deposited on the upper chamber of 0.8 μm PET wells (BD). The
lower compartment were filled with DMEM supplemented with 10% FBS.
Cells that have traveresed the membrane were fixed and stained after
22 hours. Cells in 12 different fields were counted from 3 different
chambers for each treatment. Bars represent average number of motile
cells ± SEM, n = 2.
Additional file 2: Figure S2. Effect of IMP3 knockdown on cell motility
and invasion. (A) IMP3 depletion did not affect the movement of Panc1
through transwell chambers. (B) Knocking down IMP3 resulted in a slight
decrease in the ability of L3.6pl to cover a scratch on the culture plate.
However, this trend was not found to be statistically significant. (C)
Deceasing IMP3 levels did not significantly alter the invasive ability of
Panc1.
Additional file 3: Figure S3. Effect of IMP3 knockdown on cellular
adhesion to extracellular matrix proteins. Decreasing levels of IMP3 did
not significantly alter the ability of Panc1 (A) and L3.6pl (B) to adhere to
extracellular matrix proteins. Bovine serum albumin (BSA)-coated wells
were included as negative controls. Adhesion was quantified
spectrophotometrically, and absorbance at 550 nm is proportional to the
number of adherent cells.
Additional file 4: Figure S4. Effect of IMP3 knockdown on β1 integrin
signaling in Hs766T. (A) Representative western blot of β1 integrin and
β-actin in IMP3-depleted cells and scrambled siRNA-treated control. Expression
of β1 integrin was found to be similar between IMP3-depleted cells
and scrambled siRNA-treated controls. (B) Representative western blot
of phosphorylated FAK and total FAK in IMP3 depleted cells and controls.
Levels of phosphorylated and total FAK were comparable between conditions.
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